A. Skrahina (Minsk Region, Belarus), M. De Souza Galvao (Barcelona, Spain), A. Bossink (Den Dolder, Netherlands), A. Andersen (Odense, Denmark)
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
M. Ralli, L. Stournara, E. G. Tsaroucha, M. Palavra, S. Karagiannis, V. Sgountzos, A. Papavassiliou (Athens, Greece)
|  |
Safety, tolerability and efficacy of linezolid for the treatment of M/XDR-TB: A systematic review and meta-analysis
G. Sotgiu, H. Anger, R. Centis, L. D‘Ambrsoio, S. De Lorenzo, C. Lange, G. F. Schecter, T. S. Shim, A. Skrahina, M. Villar, E. Zampogna, J. P. Zellweger, G. B. Migliori (Sassari, Tradate, Sondalo, Italy; New York, Richmond, United States Of America; Borstel, Germany; Seoul, Republic Of Korea; Minsk, Belarus; Amadora, Portugal; Lausanne, Switzerland)
|  |
Linezolid in the treatment of multi- and extensively drug-resistance tuberculosis
S. Borisov, T. Ivanushkina, N. Litvinova, Y. Garmash (Moscow, Russian Federation)
| |
Linezolide in complex treatment of XDR-TB patients
I. Vasilyeva, A. Samoilova, T. Bagdasaryan, A. Ergeshov (Moscow, Russian Federation)
| |
Adverse events in the treatment of multidrug-resistant tuberculosis
S. Qayyum, I. Ahmed, S. Baig, N. Rizvi (Karachi, Pakistan)
| |
Adverse events during treatment for latent tuberculosis infection
C. C. Dobler, G. B. Marks (Sydney, Australia)
| |
Severe adverse effects of antitubercular drugs and patient management
J. Ben Amar, B. Dhari, L. El Gharbi, M. A. Baccar, S. Azzabi, H. Aouina, H. Bouacha (Tunis, Tunisia)
| |
Individualized treatment regimens with second line anti-TB drugs (SLD) compared to first line anti-TB drug (FLD) only in new pulmonary TB patients, culture confirmed with full sensibility at drug sensibility test (DST)
D. Chiotan, C. Didilescu, N. Galie, R. Posea, C. Marica (Bucharest, Romania)
| |
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis
M. Dziusmikeyeva, A. Zalutskaya, A. Skrahin, A. Prasmyzki, V. Solodovnikova, A. Skrahina (Minsk, Belarus)
| |
Incidence and timing of hepatotoxicity due to anti-tuberculous treatment
A. Shrestha, P. Whitaker, R. Mozdiak, R. Ahmed, M. Arif, T. Capstick, J. Watson (Leeds, United Kingdom)
| |
Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit?
A. Kotti, H. Daghfous, W. Bouhawel, O. Kahloul, F. Tritar, F. Tritar (Ariana, Tunisia)
| |
Allergic reactions to rifampicin in tuberculosis treatment
F. Chermiti Ben Abdallah, I. Zayani, A. Chtourou, S. Taktak, R. Mahouachi, A. Ben Kheder (Ariana, Tunisia)
| |
Incidence of peripheral neuropathy during daily TB chemotherapy: Indian experience
T. Sahasrabudhe, V. Oswal (Pune, India)
| |
Ethambutol induced bullous and lichenoid skin eruptions
I. Akrout, E. Tangour, S. Fenniche, H. Hassene, L. Feki, D. Greb, H. Zaibi, M. L. Megdiche (Ariana, Tunisia)
| |
Research on in vitro release kinetics of isoniazid (IZN) and omeprazole from oral tablets
M. Costin, B. Cioroiu, E. Butnaru (Iasi, Romania)
| |
Influence of inhaled bronchodilator therapy on bacterioexcretion and LQ in patients with pulmonary TB infection with concomitant broncho-obstructive syndrome
G. Kuklina, E. Shmelev (Moscow, Russian Federation)
| |
In vitro susceptibility of M. avium against protionamide
T. Weiss, T. Sabha, J. Kollmeier, T. Blum, H. Mauch, H. Rüssmann, N. Schönfeld, T. T. Bauer (Berlin, Germany)
| |
Susceptibility of mycobacterium avium complex and mycobacterium xenopi to rifampin, rifapentine, clarithromycin and moxifloxacin, alone or in combination with ethambutol
C. Andrejak, D. Almeida, E. Nuermberger, J. Grosset (Baltimore, United States Of America)
| |
In vitro susceptibility of mycobacterium bovis against moxifloxacin
T. Weiss, T. Blum, J. Kollmeier, H. Mauch, H. Russmann, N. Schönfeld, T. T. Bauer (Berlin, Germany)
| |